Navigation path

Additional tools

  • Print version
  • Decrease text
  • Increase text
  • Choose high contrast version
  • Choose standard colour version




Profile of registrant

Teva Pharmaceuticals Europe BV

Identification number in the register: 27116427434-57
Registration date: 14/12/11 15:34:05

The information on this organisation was last modified on 02/01/14 14:12:26
The date of the last annual update was 20/11/13 13:29:40


Registrant : Organisation or self-employed individual

Name/company name: Teva Pharmaceuticals Europe BV
Acronym: Teva
Legal status: BV
Website address: http://www.tevapharm.com

Sections

Section: II - In-house lobbyists and trade/professional associations
and more precisely: Companies & groups

Person with legal responsibility

Surname, Name: Mr  Rob Koremans
Position: President and CEO, Teva Pharmaceuticals Europe BV

Permanent person in charge of EU relations

Surname, Name: Mr  Marcel Daniëls
Position: Vice-President European Government Affairs

Contact details:

Contact details of organisation's head office: 10 Computerweg 
Utrecht 3542 DR
NETHERLANDS
Telephone number: (+31346) 290200
Fax number: (+31346) 290289
Other contact information: Established in 1901, Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 47,000 employees worldwide, of which more than 14,000 in the European Union.

Teva specializes in development, production and marketing of a wide range of generic and branded products, as well as active pharmaceutical ingredients (API).

Teva's European Headquarters are in Utrecht, the Netherlands.

Its Brussels office is at : Square Vergote 20, 1030 Brussels. Tel: 02.739.00.10

Goals / remit

Goals / remit of the organisation: Established in 1901, Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 47,000 employees worldwide, of which more than 14,000 in the European Union.

Teva specializes in development, production and marketing of a wide range of generic and branded products, as well as active pharmaceutical ingredients (API).
The organisation's fields of interests are:
  • national
  • European
  • global

Number of persons engaged in activities falling under the scope of the Transparency Register

Number of persons: 2
Complementary information:

Persons accredited for access to European Parliament premises

First name Surname Start Date End Date
Erick Tyssier 17/04/14 15/04/15

Activities

Main EU initiatives covered the year before by activities falling under the scope of the Transparency Register:


Health and Consumer Affairs
Pharmaceutical legislation (Pharmaceutical Package, Falsified Medicines Directive, Transparency Directive)
Trade agreements
Competition (mergers and acquisition)
EU Patent and Patent Court
Access to Medicines

Fields of interest for e-mail alerts on consultations and roadmaps;

Fields declared by the organisation:
  • Competition
  • Consumer Affairs
  • Customs
  • Economic and Financial Affairs
  • Enlargement
  • Enterprise
  • External Relations
  • Humanitarian Aid
  • Information Society
  • Internal Market
  • Justice and Fundamental Rights
  • Public Health
  • Research and Technology
  • Trade

Networking

Information on (i) organisation's membership of any associations/federations/confederations or (ii) relationships to other bodies in formal or informal networks.




European Generic Medicines Association
Friends of Europe
AECA

Financial data

Financial year: 11/2012 - 11/2013
Estimated costs to the organisation directly related to representing interests to EU institutions in that year: 100000  € - 150000  €
Amount and source of funding received from the EU institutions in financial year n-1 of registration
Procurement: 0 €
Grants: 0 €
Other (financial) information provided by the organisation:


Code of conduct

By its registration the organisation has signed the Transparency Register Code of Conduct.